Speaker(s): 

Myla Deganich, DO, Resident, Geisinger - has nothing to disclose.

Lindsey Burton, MD, Resident, Geisinger - has nothing to disclose.

Moderator(s): 

Zachary Hoffer, MD, Staff Member, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Recognize the key histologic features of giant cell-rich tumors of bone and soft tissue and distinguish neoplastic cells from nonneoplastic osteoclast-like giant cells.

• Differentiate common giant cell-rich lesions using clinical location, radiologic findings, morphology, and characteristic immunohistochemical and molecular findings.

• Describe the current use, perceived benefits, and major barriers associated with implementing artificial intelligence and machine-learning systems in clinical laboratories.

• Explain the recommended approach to adopting an externally developed AI system, including vendor transparency, local verification, intended-use assessment, and ongoing performance monitoring for model drift.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Zachary Hoffer, MD PhD and Jeffrey Prichard, DO have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.